Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

瑋俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

POSTPONEMENT OF BOARD MEETING AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Wai Chun Bio-Technology Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 28 October 2026 (the "**Announcement**") in relation to the board meeting of the Company to be convened on Friday, 6 November 2026 (the "**Board Meeting**") for the purpose of, among other matters, approving the announcement of the audited annual results of the Group for the year ended 30 June 2026, and considering the payment of a final dividend, if any. Unless otherwise defined or the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

POSTPONEMENT OF BOARD MEETING AND FURTHER DELAY IN PUBLICATION OF 2026 ANNUAL RESULTS

The Auditor informed the Company that they required additional time to complete the audit process. As at the date of this announcement, the outstanding audit work includes (i) review of valuation and significant accounting estimates; and (ii) bank and audit confirmation procedures. The Board hereby announces that the Board Meeting will be adjourned and to be held on Friday, 13 November 2026.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended since 9:00 a.m. on 2 October 2026 and will remain suspended pending the publication of the 2026 Annual Results.

The Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Chairman

Hong Kong, 4 November 2026

As at the date of this announcement, the Board consists of one executive director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer) and three independent non-executive directors, namely Mr. Wong Po Keung, Mr. Wang Ziniu and Ms. Xu Huiling.